Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

112.61 +3.43 (+3.14%)
Streaming Delayed Price Updated: 1:55 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
From Merck & Co., Inc.
Via Business Wire
News headline image
1 ETF That Could Turn $100 Per Month Into $67,380 ↗
How does solid growth -- plus a 3.3% dividend yield sound? 
Via The Motley Fool
Topics ETFs Economy World Trade
News headline image
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy
As of March 13, 2026, the global financial landscape is navigating a delicate transition. Following the aggressive rate hikes of previous years and a subsequent "soft landing" throughout 2025, the U.S.... 
Via MarketMinute
Topics Artificial Intelligence Economy Workforce
News headline image
1 Unpopular Stock That Deserves Some Love and 2 We Avoid
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
Via MarketMinute
News headline image
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering... 
Via Finterra
Topics Economy Intellectual Property Lawsuit
News headline image
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
The Dow Jones (^DJI) is home to corporate giants, but size alone doesn’t guarantee success. A few of these companies are struggling with weak fundamentals, p... 
Via StockStory
Topics Stocks
News headline image
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid ↗
Eli Lilly may be the GLP-1 leader, but its valuation is stretched. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Undervalued Names Too Cheap to Ignore ↗
Via MarketBeat
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
On March 6, 2026, Moderna, Inc. (NASDAQ: MRNA) remains the centerpiece of biotech conversations following a staggering 14% surge in its share price earlier this week. For a company that became a... 
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies ↗
Merck can help stabilize investors' portfolios, whereas ImmunityBio would be a source of volatility. 
Via The Motley Fool
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
Today’s Date: March 5, 2026 Introduction The narrative surrounding Moderna, Inc. (NASDAQ: MRNA) shifted dramatically this morning as the biotechnology pioneer’s shares surged 15.99%, reclaiming a level... 
Via Finterra
Topics Intellectual Property
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise... 
Via MarketMinute
Topics Earnings Economy
News headline image
2 High-Flying Stocks With More Upside to Buy and Hold ↗
It's not too late to get in on the action. 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
News headline image
IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions ↗
To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites. 
Via Stocktwits
Topics Earnings Supply Chain
News headline image
IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗
The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
USDA Deploys $100 Million 'Screwworm Challenge' to Safeguard U.S. Livestock and Dairy Frontier
The United States Department of Agriculture (USDA) has officially greenlit a massive $100 million initiative dubbed the "Screwworm Challenge," aimed at neutralizing a resurgent biological threat that... 
Via MarketMinute
Topics Economy
News headline image
IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend ↗
Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
From Merck & Co., Inc
Via Business Wire
News headline image
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Big Tech’s Heavy Lifting: S&P 500 Q4 Earnings Surpass 8% Growth Amid AI Capex Anxiety
As the final reports of the fourth-quarter earnings season trickled in through late February 2026, the S&P 500 demonstrated a resilient performance that caught many analysts by surprise. The benchmark... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
What's going on in today's session: S&P500 movers ↗
Via Chartmill
News headline image
Industrial Renaissance: Sector Surges 27% in Q4 2025 as Healthcare and Consumer Discretionary Lag
The fourth-quarter 2025 earnings season has delivered a definitive verdict on the health of the American economy: the "Industrial Renaissance" is no longer a forecast, but a realized phenomenon. While... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir... 
Via MarketMinute
Topics Intellectual Property
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Moonshot Medicine: United Therapeutics Surges on Record Earnings and TreSMI Breakthrough
United Therapeutics Corporation (Nasdaq: UTHR) has long been a favorite of biotech investors who value both steady cash flows and visionary "moonshot" projects. On February 25, 2026, the company... 
Via Finterra
Topics Earnings Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.